SCHEMBL5523040

SCHEMBL5523040

CCCO[C@@H]1[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@@H](CO)O[C@H]1O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 5/20 0.53
LGALS8 O00214 3/20 0.53
LGALS4 P56470 3/20 0.53
GJB2 P29033 2/20 0.49
AMY2A P04746 3/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LGALS9 O00182 1/20 0.43
LGALS1 P09382 1/20 0.43
LGALS7; LGALS7B P47929 1/20 0.43
GJA1 P17302 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 1/20 0.43
IGF2R P11717 1/20 0.43
TYR P14679 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18160494 1.00 LGALS3 (0.53) LGALS3LGALS8LGALS4GJB2AMY2A
SCHEMBL21813015 0.92 LGALS8 (0.57) LGALS3LGALS8LGALS4GJB2AMY2A
SCHEMBL20262949 0.90 GJB2 (0.61) LGALS3LGALS8LGALS4GJB2
SCHEMBL7779160 0.90 GJB2 (0.61) LGALS3LGALS8LGALS4GJB2
SCHEMBL411272 0.90 GJB2 (0.61) LGALS3LGALS8LGALS4GJB2
SCHEMBL411623 0.90 GJB2 (0.61) LGALS3LGALS8LGALS4GJB2
SCHEMBL10261434 0.87 LGALS3 (0.67) LGALS3LGALS8LGALS4GJB2MEN1
SCHEMBL6815726 0.87 LGALS3 (0.67) LGALS3LGALS8LGALS4GJB2MEN1
SCHEMBL10292030 0.87 LGALS3 (0.67) LGALS3LGALS8LGALS4GJB2MEN1
SCHEMBL17547757 0.87 LGALS3 (0.67) LGALS3LGALS8LGALS4GJB2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070042030-A1 Preparation for the application of agents in mini-droplets IDEA AG (DE) 2007-02-22 US disclosed
EP-0475160-B2 Preparation for drug application in minute droplet form IDEA AG (DE) 2004-07-14 EP disclosed
US-6165500-A Preparation for the application of agents in mini-droplets IDEA AG (DE) 2000-12-26 US disclosed
EP-0475160-B1 Preparation for drug application in minute droplet form IDEA AG (DE) 1996-02-14 EP disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 EP disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042030-A1 Preparation for the application of agents in mini-droplets FABP4, NPC1L1, LIPA LGALS3 347/4885LGALS8 437/4885LGALS4 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.